{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:52:04Z","timestamp":1793962324128,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with pancreatic ductal adenocarcinoma (PDAC) commonly have occult metastatic dissemination and current standard staging methods have significant limitations in identifying these patients. A clinically available assay allows for the identification of mutant KRAS (mKRAS) circulating tumor DNA (ctDNA) from patient plasma and peritoneal fluid that may identify these patients and impact treatment decision making. We investigated the patterns of diagnostic and prognostic capabilities of mKRAS ctDNA in patients with localized PDAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with non-metastatic PDAC were identified and underwent a full staging work-up during their first visit at our institution. Development of metastatic disease and long-term survival outcomes were assessed to compare between the mKRAS testing groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between 2018 and 2022, 785 patients were evaluated. Among the 785 patients who underwent plasma mKRAS testing, 104 were mKRAS positive. Plasma mKRAS-positive patients were more likely to develop metastatic disease and had worse overall survival. In the 419 patients who underwent peritoneal mKRAS, 123 were mKRAS-positive and were more likely to harbor occult metastases or develop peritoneal rather than hematogenous metastases. For patients who underwent both baseline plasma and peritoneal mKRAS testing, any positive mKRAS test regardless of compartment was associated with worse outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Detection of mKRAS ctDNA in plasma and peritoneal fluid of patients with localized PDAC is not only feasible but also identifies those at high risk of metastatic progression and worse survival outcomes. It allows for better prognostication and can significantly impact subsequent treatment decisions, particularly in patients where an aggressive surgical approach is being considered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17036-y","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:31:43Z","timestamp":1741707103000},"page":"4453-4463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study"],"prefix":"10.1245","volume":"32","author":[{"given":"Jennifer L.","family":"Leiting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Alva-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Yonkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac T.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva R.","family":"Salomao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius A.","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Kipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"17036_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. JAMA. 2013;310:1473\u201381.","journal-title":"JAMA."},{"key":"17036_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med."},{"key":"17036_CR3","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1097\/RLU.0000000000000837","volume":"40","author":"R Kim","year":"2015","unstructured":"Kim R, Prithviraj G, Kothari N, et al. PET\/CT fusion scan prevents futile laparotomy in early stage pancreatic cancer. Clin Nucl Med. 2015;40:e501\u20135.","journal-title":"Clin Nucl Med."},{"key":"17036_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","volume":"20","author":"A Abdelrahman","year":"2022","unstructured":"Abdelrahman A, Goenka A, Alva-Ruiz R, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable\/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1023\u201332.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"17036_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.hbpd.2022.02.003","volume":"21","author":"E Sahlstrom","year":"2022","unstructured":"Sahlstrom E, Bereza-Carlson P, Nilsson J, Tingstedt B, Andersson B. Risk factors and outcomes for patients with pancreatic cancer undergoing surgical exploration without resection due to metastatic disease: a national cohort study. Hepatobiliary Pancreat Dis Int. 2022;21(3):279\u201384.","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"17036_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jamcollsurg.2016.02.009","volume":"223","author":"JR Bergquist","year":"2016","unstructured":"Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate antigen 19\u20139 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study. J Am Coll Surg. 2016;223:52\u201365.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"17036_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","volume":"237","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Yonkus J, Alva-Ruiz R, et al. Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of over 1000 consecutive patients. J Am Coll Surg. 2023;237(1):49\u201357.","journal-title":"J Am Coll Surg."},{"key":"17036_CR8","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-008-0134-5","volume":"15","author":"SK Maithel","year":"2008","unstructured":"Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19\u20139 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512\u201320. https:\/\/doi.org\/10.1245\/s10434-008-0134-5.","journal-title":"Ann Surg Oncol."},{"key":"17036_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/bjs.9307","volume":"100","author":"S Yamada","year":"2013","unstructured":"Yamada S, Fujii T, Kanda M, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg. 2013;100:1791\u20136.","journal-title":"Br J Surg."},{"issue":"1","key":"17036_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jamcollsurg.2021.05.009","volume":"233","author":"J Yonkus","year":"2021","unstructured":"Yonkus J, Alva-Ruiz R, Abdelrahman A, et al. Molecular peritoneal staging for pancreatic ductal adenocarcinoma using mutant KRAS droplet-digital polymerase chain reaction: results of a prospective clinical trial. J Am Coll Surg. 2021;233(1):73\u201380.","journal-title":"J Am Coll Surg."},{"key":"17036_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479\u201391.","journal-title":"Cancer Discov."},{"key":"17036_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985\u201390.","journal-title":"Nat Med."},{"key":"17036_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","volume":"142","author":"M Kanda","year":"2013","unstructured":"Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2013;142:730\u20133.","journal-title":"Gastroenterology."},{"key":"17036_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc2899","volume":"10","author":"JP Morris","year":"2010","unstructured":"Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10:683\u201395.","journal-title":"Nat Rev Cancer."},{"key":"17036_CR15","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1373\/clinchem.2018.291278","volume":"64","author":"D Milosevic","year":"2018","unstructured":"Milosevic D, Mills JR, Campion MB, et al. Applying standard clinical chemistry assay validation to droplet digital PCR quantitative liquid biopsy testing. Clin Chem. 2018;64:1732\u201342.","journal-title":"Clin Chem."},{"key":"17036_CR16","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.cgh.2018.02.048","volume":"16","author":"MJ Levy","year":"2018","unstructured":"Levy MJ, Kipp BR, Milosevic D, et al. Analysis of cell-free DNA to assess risk of tumoremia following endoscopic ultrasound fine-needle aspiration of pancreatic adenocarcinomas. Clin Gastroenterol Hepatol. 2018;16:1632-1640e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"17036_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1245\/s10434-011-2211-4","volume":"19","author":"CW Tzeng","year":"2012","unstructured":"Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19:2045\u201353. https:\/\/doi.org\/10.1245\/s10434-011-2211-4.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"17036_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamasurg.2015.0668","volume":"150","author":"A Paniccia","year":"2015","unstructured":"Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150(8):701\u201310.","journal-title":"JAMA Surg."},{"issue":"11","key":"17036_CR19","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.hpb.2021.04.004","volume":"23","author":"S Crippa","year":"2021","unstructured":"Crippa S, Belfiori G, Bissolati M, et al. Recurrence after surgical resection of pancreatic cancer: the important of postoperative complications beyond tumor biology. HPB. 2021;23(11):1666\u201373.","journal-title":"HPB."},{"key":"17036_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12885-015-1779-7","volume":"15","author":"J Earl","year":"2015","unstructured":"Earl J, Garcia-Nieto S, Martinez-Avila JC, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (ctDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797.","journal-title":"BMC Cancer."},{"issue":"5","key":"17036_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","volume":"23","author":"R Perets","year":"2018","unstructured":"Perets R, Greenberg O, Shentzer T, et al. KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist. 2018;23(5):566\u201372.","journal-title":"Oncologist."},{"key":"17036_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/bjc.2016.175","volume":"115","author":"N Hadano","year":"2016","unstructured":"Hadano N, Murakami Y, Uemura K, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115:59\u201365.","journal-title":"Br J Cancer."},{"issue":"5","key":"17036_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bjc.2017.479","volume":"118","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, Kitago M, Matsuda S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118(5):662\u20139.","journal-title":"Br J Cancer."},{"key":"17036_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","volume":"18","author":"T Wei","year":"2019","unstructured":"Wei T, Zhang Q, Li X, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther. 2019;18:196\u2013203.","journal-title":"Mol Cancer Ther."},{"key":"17036_CR25","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","volume":"30","author":"B Lee","year":"2019","unstructured":"Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30:1472\u20138.","journal-title":"Ann Oncol."},{"key":"17036_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.amjsurg.2010.01.021","volume":"199","author":"CJ Clark","year":"2010","unstructured":"Clark CJ, Traverso LW. Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg. 2010;199:657\u201362.","journal-title":"Am J Surg."},{"key":"17036_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.surg.2016.10.035","volume":"161","author":"T Abe","year":"2017","unstructured":"Abe T, Ohuchida K, Endo S, et al. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Surgery. 2017;161:951\u20138.","journal-title":"Surgery."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17036-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:15:18Z","timestamp":1746288918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17036"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17036-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jennifer L. Leiting, Roberto Alva-Ruiz, Jennifer A. Yonkus, Amro M. Abdelrahman, Isaac T. Lynch, Danielle M. Carlson, Ryan M. Carr, Diva R. Salomao, Robert R. McWilliams, Patrick P. Starlinger, Cornelius A. Thiels, Travis E. Grotz, Susanne G. Warner, Sean P. Cleary, Michael L. Kendrick, Rory L. Smoot, Benjamin R. Kipp, and Mark J. Truty have no financial or conflicts of interest disclosures to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}